SciBase Holding AB
Company Profile
Business description
SciBase Holding AB is a medical technology company that develops devices for the evaluation of skin disorders such as skin cancer and atopic dermatitis. SciBase’s products include Nevisense and Nevisense Go and to date, the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection, and skin barrier assessment. It is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. The company operates in two segments which includes skin cancer and skin barrier assessment. Majority of the revenue is generated from skin cancer segment. Its geographical segments are Europe/Rest of the World, the United States/North America, and Asia/Oceania.
Contact
Landsvagen 39
Sundbyberg
Stockholm172 63
SWET: +46 841062000
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2024
Employees
27
Stocks News & Analysis
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
stocks
Is this overpriced ASX share too much of a gamble?
stocks
ASX players that might thrive under a Trump administration
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,479.90 | 29.00 | 0.34% |
| CAC 40 | 7,311.80 | 94.97 | 1.32% |
| DAX 40 | 19,263.70 | 260.59 | 1.37% |
| Dow JONES (US) | 43,750.86 | 207.33 | -0.47% |
| FTSE 100 | 8,071.19 | 40.86 | 0.51% |
| HKSE | 19,435.81 | 387.64 | -1.96% |
| NASDAQ | 19,107.65 | 123.07 | -0.64% |
| Nikkei 225 | 38,535.70 | 185.96 | -0.48% |
| NZX 50 Index | 12,709.09 | 16.15 | 0.13% |
| S&P 500 | 5,949.17 | 36.21 | -0.60% |
| S&P/ASX 200 | 8,224.00 | 30.60 | 0.37% |
| SSE Composite Index | 3,379.84 | 59.44 | -1.73% |